Skip to main content

COVID 19 Updates from RheumNow

Safety of COVID-19 Vaccines in Rheumatic Patients

Since the introduction of COVID-19 vaccines in January 2021, rheumatologists have fully advocated the protective benefits of their use - yet many have rarely noted flares and reactive side effects worrisome to patients.  Now a multinational study shows that the use of COVID vaccination in rh

Best of 2021: Jack of All Subspecialties

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Best of 2021: Tofacitinib Safety Concerns

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Best of 2021: Zoomatology – Present in Absentia

Zoom has become the slam dunk answer to the pandemic. With zoom you can avoid congregations, but still attend and belong.  Because of zoom you can sustain your business and continue medical care.  With zoom, learning moved from the classroom to the dining room for all.

Best of 2021: My Personal Delta COVID-19 Breakthrough Infection

As many of you are aware, I have written and spoken on COVID-19 extensively over these past 20 months, and just last month wrote about the dangers of the delta variant. In July, things took an unexpected turn when I developed a breakthrough infection with the delta variant.

Best of 2021: Consults in Cars

In this episode of Dialing for Doctors (AKA Tales of Telehell), we will consider a growing subset of telehealth seekers connecting from their cars.

I don’t mean they are driving to the clinic, or driving to a virtual care center.  

Best of 2021: Rebuttals

Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccine hesitant. 

Indications Awaiting (12.17.21)

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Serious Adverse Events Associated with Tocilizumab in COVID-19 Patients

Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.

Social

Everyday heroes during #COVID19 Keynote @ACRheum Health care workers who were minorities disproportionately died in the early days of the pandemic. Can’t be all SES as risk but maybe ‘status’ as first line workers. Remember them #ACRBest #ACR22 @RheumNow @AbrahamVerghese 🙏🏻 https://t.co/AjkV5wDVEu
2 years ago
Please read my short review on early experience/data pertaining to the use of #Evusheld in patients with rheumatic and musculoskeletal diseases presented at #ACR22 @RheumNow https://t.co/JA7WsWqMmz https://t.co/MRA0mQFIu8
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years ago
Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts? Single-center (n=126) with one MTX dose WH post-each vaccine Similar humoral response Big error bars suggest other factors more important ABST0913 #ACR22 @RheumNow (not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY
David Liew @drdavidliew ( View Tweet )
2 years ago
💉COVID-19 vaccination in pregnant pts with rheumatic disease💉 🤰⬇️pre term births in vaccinated 🤰PPROM ⬆️ unvaccinated ✅More support 4 importance of covid vacc in our 🤰 Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W
Patricia Harkins @DrTrishHarkins ( View Tweet )
2 years ago
#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years ago
Ab0685 #ACR22 APLS and prior COVID infection TKR patients at HSS: 1/5 of patients had positive aPL Ab, mostly low level aCL IgM Not associated with COVID infection or SARS-CoV-2 Ab @RheumNow https://t.co/HJpnUOrrxc
2 years ago
Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 years ago
Getting to know the COVID-19 drugs: ◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld) ◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV) Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Dr. Antoni Chan @synovialjoints ( View Tweet )
2 years ago
Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow
2 years ago
We share our vision of what rheumatologists should be considering thinking and doing regarding COVID-19 in our immunocompromise patients. Would love your reactions @CCalabreseDO @BetsyKirch @DrPujaMehta1 @alhkim @drdavidliew @philipcrobinson #ACR22 https://t.co/OpmoEOXWmL

Leonard Calabrese @LCalabreseDO ( View Tweet )

2 years ago
×